Literature DB >> 15657041

Steric accessibility of the HIV-1 gp41 N-trimer region.

Agnes E Hamburger1, Sunghwan Kim, Brett D Welch, Michael S Kay.   

Abstract

During human immunodeficiency virus entry, gp41 undergoes a series of conformational changes that induce membrane fusion. Immediately prior to fusion, gp41 exists in a prehairpin intermediate in which the N- and C-peptide regions of gp41 are exposed. Rearrangement of this intermediate into a six-helix bundle composed of a trimeric coiled coil from the N-peptide region (N-trimer) surrounded by three peptides from the C-peptide region provides the driving force for membrane fusion, whereas prevention of six-helix bundle formation inhibits viral entry. Because of its central role in mediating viral entry, the N-trimer region of gp41 is a key vaccine target. Extensive efforts to discover potent and broadly neutralizing antibodies (Abs) against the N-trimer region have, thus far, been unsuccessful. In this study, we attached a potent C-peptide inhibitor that binds to the N-trimer region to cargo proteins of various sizes to examine the steric accessibility of the N-trimer during fusion. These inhibitors show a progressive loss of potency with increasing cargo size. Extension of the cargo/C-peptide linker partially restores inhibitory potency. These results demonstrate that the human immunodeficiency virus defends its critical hairpin-forming machinery by steric exclusion of large proteins and may explain the current dearth of neutralizing Abs against the N-trimer. In contrast, previous results suggest the C-peptide region is freely accessible during fusion, demonstrating that the N- and C-peptide regions are in structurally distinct environments. Based on these results, we also propose new strategies for the generation of neutralizing Abs that overcome this steric block.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657041     DOI: 10.1074/jbc.M412770200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Authors:  Min Zhuang; Wei Wang; Christopher J De Feo; Russell Vassell; Carol D Weiss
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

2.  Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.

Authors:  Cheryl A Stoddart; Geneviève Nault; Sofiya A Galkina; Nathalie Bousquet-Gagnon; Dominique Bridon; Omar Quraishi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

3.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

4.  Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.

Authors:  Xi Chen; Lu Lu; Zhi Qi; Hong Lu; Ji Wang; Xiaoxia Yu; Yinghua Chen; Shibo Jiang
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

5.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.

Authors:  Antony S Dimitrov; John M Louis; Carole A Bewley; G Marius Clore; Robert Blumenthal
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

6.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Authors:  Michael D Miller; Romas Geleziunas; Elisabetta Bianchi; Simon Lennard; Renee Hrin; Hangchun Zhang; Meiqing Lu; Zhiqiang An; Paolo Ingallinella; Marco Finotto; Marco Mattu; Adam C Finnefrock; David Bramhill; James Cook; Debra M Eckert; Richard Hampton; Mayuri Patel; Stephen Jarantow; Joseph Joyce; Gennaro Ciliberto; Riccardo Cortese; Ping Lu; William Strohl; William Schleif; Michael McElhaugh; Steven Lane; Christopher Lloyd; David Lowe; Jane Osbourn; Tristan Vaughan; Emilio Emini; Gaetano Barbato; Peter S Kim; Daria J Hazuda; John W Shiver; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

7.  The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.

Authors:  Jing-He Huang; Heng-Wen Yang; Shuwen Liu; Jing Li; Shibo Jiang; Ying-Hua Chen
Journal:  Biochem J       Date:  2007-05-01       Impact factor: 3.857

8.  Potent D-peptide inhibitors of HIV-1 entry.

Authors:  Brett D Welch; Andrew P VanDemark; Annie Heroux; Christopher P Hill; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

9.  Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Authors:  Kelly Champagne; Akira Shishido; Michael J Root
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

10.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.